Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
18.34
-0.02 (-0.11%)
At close: Sep 26, 2025, 4:00 PM EDT
18.49
+0.15 (0.82%)
After-hours: Sep 26, 2025, 7:58 PM EDT
Teva Pharmaceutical Revenue
Teva Pharmaceutical had revenue of $4.18B in the quarter ending June 30, 2025, with 0.29% growth. This brings the company's revenue in the last twelve months to $16.63B, up 2.07% year-over-year. In the year 2024, Teva Pharmaceutical had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
$16.63B
Revenue Growth
+2.07%
P/S Ratio
1.26
Revenue / Employee
$451,480
Employees
36,830
Market Cap
21.04B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TEVA News
- 2 days ago - Teva Releases Q3 2025 Aide Memoire - GlobeNewsWire
- 2 days ago - Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025 - GlobeNewsWire
- 2 days ago - Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors - Seeking Alpha
- 3 days ago - Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 5 days ago - Teva Pharmaceutical Industries Limited - Special Call - Seeking Alpha
- 7 days ago - New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed - GlobeNewsWire
- 10 days ago - Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation - Business Wire
- 11 days ago - Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting - GlobeNewsWire